Erotokritou-Mulligan Ioulietta, Bassett E Eryl, Bartlett Christiaan, Cowan David, McHugh Cathy, Seah Rick, Curtis Benjamin, Wells Victoria, Harrison Kate, Sönksen Peter H, Holt Richard I G
The Institute of Developmental Sciences (IDS Building), MP887, University of Southampton, Southampton General Hospital, Tremona Road, Southampton United Kingdom.
J Clin Endocrinol Metab. 2008 Jul;93(7):2760-3. doi: 10.1210/jc.2007-2801. Epub 2008 Apr 15.
A method to detect exogenously administered growth hormone (GH) based on the measurement of two GH-dependent markers, IGF-I and type 3 procollagen (P-III-P) has been proposed. Skeletal or soft tissue injury may alter these markers. Elevations in either of these proteins after injury might lead to a false accusation of doping with GH.
The objective of the study was to assess the effect of musculoskeletal or soft tissue injury on IGF-I and P-III-P concentrations in amateur and elite athletes and assess the effect of injury on the proposed GH detection method.
This was a longitudinal observational study after sporting injury.
The study was conducted at Southampton General Hospital and British Olympic Medical Centre.
Subjects included elite and amateur athletes after an injury.
Interventions included measurement of IGF-I and P-III-P and application of the GH-2000 discriminant function score up to 84 d after an injury as well as classification of injury by type and severity.
IGF-I and P-III-P concentration and ability to detect GH abuse in athletes without the risk of false accusation because of an injury were measured.
There was no change in IGF-I concentration after an injury. By contrast, P-III-P concentrations rose by 41.1 +/- 16.6%, reaching a peak around 14 d after an injury. The rise in P-III-P varied according to injury type and severity. This rise had a trivial effect on the GH-2000 discriminant function score, and no subject reached the threshold needed for a doping offense.
Although there was a rise in P-III-P after injury, this was insufficient to invalidate the GH-2000 detection method based on IGF-I and P-III-P concentrations.
有人提出了一种基于测量两种生长激素(GH)依赖性标志物——胰岛素样生长因子-I(IGF-I)和Ⅲ型前胶原(P-III-P)来检测外源性施用生长激素的方法。骨骼或软组织损伤可能会改变这些标志物。损伤后这两种蛋白质中任何一种的升高都可能导致对使用生长激素进行兴奋剂指控的误判。
本研究的目的是评估肌肉骨骼或软组织损伤对业余和精英运动员中IGF-I和P-III-P浓度的影响,并评估损伤对所提出的生长激素检测方法的影响。
这是一项运动损伤后的纵向观察性研究。
该研究在南安普敦总医院和英国奥林匹克医疗中心进行。
受试者包括受伤后的精英和业余运动员。
干预措施包括测量IGF-I和P-III-P,并在受伤后长达84天应用GH-2000判别功能评分,以及按类型和严重程度对损伤进行分类。
测量IGF-I和P-III-P浓度以及在不因损伤而有误判风险的情况下检测运动员滥用生长激素的能力。
受伤后IGF-I浓度没有变化。相比之下,P-III-P浓度上升了41.1±16.6%,在受伤后约14天达到峰值。P-III-P的上升因损伤类型和严重程度而异。这种上升对GH-2000判别功能评分影响很小,没有受试者达到兴奋剂违规所需的阈值。
虽然受伤后P-III-P有所上升,但这不足以使基于IGF-I和P-III-P浓度的GH-2000检测方法无效。